

Included in NCCN and AUA Guidelines

| | NCCN Guidelines | AUA Guidelines |
|------------------------|-----------------|----------------|
| Select mdx | ✓ | |
| Confirm mdx | ✓ | |
| Genomic Prostate Score | ✓ | ✓ |

References

- ¹ Independently published clinical studies have shown that for men who have received a negative prostate biopsy result, Confirm mdx is the single most significant predictor of patient outcome among all currently available clinical factors, such as age, PSA level, and DRE results.
- ¹ Haese A, et al. (2019) Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. *J Urol.* 2019 Aug;202(2):256-263.
- ² Van Neste L, et al. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. *Prostate.* 2016;76(12):1078-1087. doi:10.1002/pros.23191.

Mdxhealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. This test was developed, and its performance characteristics determined by Mdxhealth. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined such clearance or approval is not necessary.

Precision prostate cancer pathway

Bring clarity to prostate cancer management.



With a menu of molecular diagnostic tests targeting biomarkers proven for clinical utility, the mdxhealth precision prostate cancer pathway aligns with the physician and patient's desire for informed, confident decision-making at every step.

For pre-biopsy

Select mdx
for Prostate Cancer

For negative biopsies

Confirm mdx
for Prostate Cancer


For positive biopsies

Genomic
Prostate Score

Precision prostate cancer pathway

is a menu of non-invasive prostate cancer tests designed to aid physicians in providing more precise and personalized patient care while helping to reduce the unnecessary invasive procedures, treatments, costs and patient anxiety associated with the disease.

- Initial biopsy decision (**Select mdx**)
- Post negative biopsy decision (**Confirm mdx**)
- Localized prostate cancer treatment decision (**Genomic Prostate Score**)



Select mdx

With an unparalleled specificity for predicting clinically significant cancer, Select mdx can help better stratify your patients, identifying those that may benefit from a biopsy.



Urine test
("liquid biopsy")



95% NPV for GS ≥ 7
Prostate Cancer¹

Confirm mdx

Proven to be the most significant predictor of prostate cancer detection on repeat biopsy*, Confirm mdx addresses the challenges of prostate sampling error and false-negative biopsies, helping to focus on finding and treating aggressive cancers.



Examines prostate biopsy tissue at the DNA level



96% NPV for GS ≥ 7
Prostate Cancer²

Genomic Prostate Score

Analyzes tumor biology to predict disease aggressiveness among men with low to high-risk disease. Results help guide treatment decisions with clinically meaningful endpoints at the time of diagnosis.

